Viral vectors in the treatment of Parkinson's disease

Movement Disorders

Volumn 15, Issue 1, 2000, Pages 9-17

  Latchman, David S ^a   Coffin, Robert S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

GDNF; Gene therapy; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SIMPLEXVIRUS; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 0033981804     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200001)15:1<9::AID-MDS1004>3.0.CO;2-5     Document Type: Review

References (45)

1. Miller AD. Human gene therapy comes of age. Nature 1992;357: 455-460.
2. French Anderson W. Human gene therapy. Nature 1998;392 (suppl):25-30.
3. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1996;247:574-577.
4. Widner H, Tetrud J, Rehncrona S. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327:1556-1563.
5. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109.
6. Freese A, Stern M, Kaplitt MG, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996;11:469-488.
7. Bencsjcs C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-dopa by primary fibroblasts. J Neurosci 1996;16:4449-4456.
8. Uchida K, Tsuzaki N, Nagatsu T, Kohsaka S. Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA. Dev Neurosci 1992;14:173-180.
9. Lin L-FH, Doherty DH, Lile JD, Bekthesh S, Collins F. A glial cell-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
10. Lapchak PA, Miller PJ, Jiao SS, Araujo DM, Hilt D, Collins R. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 1996;5:197-205.
11. Lapchak PA. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev Neurosci 1996;7:165-176.
12. Hynes M, Porter JA, Chiang C, et al. Induction of midbrain dopaminergic neurons by sonic hedgehog. Neuron 1995;15:35-44.
13. Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996.
14. Miller AG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
15. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 1991;6:371-380.
16. Jiao S, Schultz E, Wolff JA. Intracerebral transplants of primary muscle cells: a potential 'platform' for transgene expression in the brain. Molecular Brain Research 1992;575:143-147.
17. Senut M-C, Suhr ST, Gage FH. Transplantation of genetically modified non-neuronal cells in the central nervous system. In: Latchman D, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:181-202.
18. Tsuda M, Imaokea T. Direct injection of plasmid DNA into the brain. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:235-248.
19. Horellou P, Vigne E, Castel MN, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 1994;6:49-53.
20. Bilang-Bleuel A, Revah F, Colin P, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997;94:8818-8823.
21. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
22. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydoxylase. Science 1994;266:1399-1403.
23. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998;18:4271-4284.
24. Roizman B, Sears AE. An inquiry into the mechanisms of herpes simplex virus latency. Annu Rev Microbiol 1987;41:543-571.
25. Latchman DS. Molecular biology of herpes simplex virus latency. Int J Exp Pathol 1990;71:133-141.
26. Fink DJ, DeLuca NA, Goins WF, Glorioso JC. Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci 1996;19:265-287.
27. Kennedy GE. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain 1997;120:1245-1259.
28. Coffin RS, Latchman DS. Herpes simplex virus based vectors. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:99-114.
29. Latchman DS. Herpes simplex virus vectors for gene therapy. Biogenic Amines 1998;14:477-497.
30. Chiocca AE, Choi BB, Cai W, et al. Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants. New Biologist 1990;266:739-746.
31. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT. A latent nonpathogenic HSV-1 derived vector stably expresses b galactosidase in mouse neurons. Neuron 1990;5:353-360.
32. Howard MK, Kershaw T, Gibb B, et al. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene Ther 1998;5:1137-1147.
33. Maclean AR, Fareed MU, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pin-point neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the 'a' sequence. J Gen Virol 1991;72:631-639.
34. Ace CI, McKee TA, Ryan M, Cameron JM, Preston CM. Construction and characterization of a herpes simplex virus type 1 mutant unable to transduce immediate-early gene expression. J Virol 1989;63:2260-2269.
35. Goding CR, O'Hare P. Herpes simplex virus Vmw65-octamer binding protein interaction: a paradigm for combinatorial control of transcription. Virology 1989;173:363-367.
36. Coffin RS, Howard MK, Cumming DVE, et al. Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors. Gene Ther 1996;3:560-566.
37. Margolis TP, Bloom DC, Dobson AT, Feldman LT, Stevens JG. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. Virology 1993;197:585-592.
38. Margolis TP, Sedarati F, Dobson AT, Feldman LT, Stevens JG. Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology 1992;189:150-160.
39. Dobson AT, Margolis TP, Gomes WA, Feldman LT. In vivo deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter. J Virol 1995;69:2264-2270.
40. Ho DY, Mocarski ES. Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse. Proc Natl Acad Sci USA 1989;86:7596-7600.
41. Goins WF, Stenberg LR, Croen KD, et al. A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats. J Virol 1994;68:2239-2252.
42. Wang Q, Guo J, Jia W. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther 1997;4:1300-1304.
43. Rampling R, Cruickshank G, Maclean AR, Brown SM. Therapeutic replication competent herpes virus. Nat Med 1999;2:133.
44. Wagstaff MJD, Collaco-Moraes Y, Smith J, de Belleroche J, Coffin RS, Latchman DS. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem 1999;274:5061-5069.
45. Smith MD, Ensor EA, Coffin RS, Boxer LM, Latchman DS. Bcl-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor. J Biol Chem 1997;273:16715-16722.